NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
Stocks in this Quantisnow insightHealth Care
Historical context for NCEL
Across the 9 sessions after earlier NCEL headlines, the stock closed higher 6 times and lower 3 times, with a median move of 6.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NCEL | SPY |
|---|---|---|---|
| Jul 8, 2026 | NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | +5.5% | -0.3% |
| Jun 15, 2026 | NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform | -0.9% | +1.8% |
| Apr 1, 2026 | NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | +10.8% | +0.8% |
| Feb 12, 2026 | NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy | +1.1% | -1.5% |
| Jan 29, 2026 | NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences | -3.4% | -0.2% |
| Jan 12, 2026 | NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression | +13.7% | +0.2% |
Quantisnow market dataNASDAQ
NCEL
NewcelX Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for NCEL
Full NCEL profile on Quantisnow Follow NCEL and get a push notification the moment its next story breaks.